{
    "organizations": [],
    "uuid": "f0a512ec0588dfebab14300df1f34697751fc61c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bio-path-holdings-announces-interi/brief-bio-path-holdings-announces-interim-data-from-phase-2-clinical-trial-of-prexigebersen-idUSASC09UNA",
    "ord_in_thread": 0,
    "title": "BRIEF-Bio-Path Holdings Announces Interim Data From Phase 2 Clinical Trial Of Prexigebersen",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Bio Path Holdings Inc:\n* PATH HOLDINGS ANNOUNCES INTERIM DATA FROM PHASE 2 CLINICAL TRIAL OF PREXIGEBERSEN IN COMBINATION WITH LOW DOSE CYTARABINE (LDAC) FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)\n* BIO PATH HOLDINGS INC - PREXIGEBERSEN PLUS LDAC WAS WELL-TOLERATED\n* LEUKEMIC ACTIVITY IN NEARLY 50% OF EVALUABLE AML PATIENTS TREATED TO DATE​\n* ‍ AMENDING PROTOCOL TO CHANGE DOSING SCHEDULE TO THAT USED IN PHASE 1B STUDY IN RELAPSED AND REFRACTORY AML PATIENTS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T19:36:00.000+03:00",
    "crawled": "2018-04-04T12:32:31.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "bio",
        "path",
        "holding",
        "inc",
        "path",
        "holding",
        "announces",
        "interim",
        "data",
        "phase",
        "clinical",
        "trial",
        "prexigebersen",
        "combination",
        "low",
        "dose",
        "cytarabine",
        "ldac",
        "treatment",
        "acute",
        "myeloid",
        "leukemia",
        "aml",
        "bio",
        "path",
        "holding",
        "inc",
        "prexigebersen",
        "plus",
        "ldac",
        "leukemic",
        "activity",
        "nearly",
        "evaluable",
        "aml",
        "patient",
        "treated",
        "amending",
        "protocol",
        "change",
        "dosing",
        "schedule",
        "used",
        "phase",
        "1b",
        "study",
        "relapsed",
        "refractory",
        "aml",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}